Medical Communications - the Next Big Thing?
The recent ‘PR war’ between pharmaceutical giant, Roche and the National Institute for Health and Care Excellence (NICE) over the latter’s rejection of the breast cancer drug, Kadcyla has shown how important the role of comms professionals has become in the life sciences sector.
“Drugs companies have moved from long-term development of big-hitter therapies to producing medicines that target very specific conditions,” says Lucinda Moores, Practice Director at corporate communications recruitment specialist, VMA Group. “This means more drugs coming onto the market faster and a higher rejection rate by bodies such as NICE because of budgetary constraints. We’re consequently likely to see more and more focus on shaping and communicating the case for these treatments, not just through conventional channels, but increasingly across public media.”
According to VMA Group’s research this is likely to dramatically increase the already high demand for medical communications professionals.
“We fully expect that the most senior and technical roles in medical communications will continue to be held by individuals with masters and PhDs in life sciences and even by trained medical doctors. However, increasing pressures in the area are also likely to mean that both corporations and agencies will need to draw in talent from other parts of the PR industry to provide support and wider communication skills. Medical communications is consequently set to be a magnet for some of the best comms talent available over the next few years.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.